Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $237000.0.

  • Centessa Pharmaceuticals' Depreciation & Amortization (CF) rose 42.37% to $237000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $910000.0, marking a year-over-year decrease of 501.04%. This contributed to the annual value of $942000.0 for FY2024, which is 1629.63% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Depreciation & Amortization (CF) is $237000.0, which was up 42.37% from $226000.0 recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $246000.0 in Q4 2023 and a low of $28000.0 during Q1 2022
  • Moreover, its 4-year median value for Depreciation & Amortization (CF) was $230000.0 (2024), whereas its average is $170866.7.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Depreciation & Amortization (CF) skyrocketed by 64062.5% in 2023, and later tumbled by 958.33% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $36000.0 in 2022, then surged by 583.33% to $246000.0 in 2023, then fell by 6.5% to $230000.0 in 2024, then rose by 3.04% to $237000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $237000.0 for Q3 2025, versus $226000.0 for Q2 2025 and $217000.0 for Q1 2025.